This site is fictional demo content. It is not real news or affiliated with any real organization. Do not treat it as fact or professional advice.

Full article

FULL TEXT

View this issue
Deep diveAI

Molecular Communication Protocol MoleculeLink Deep Dive: Replacing Electromagnetic Waves with Biological Molecules for Nano-Device Communication

Molecular communication protocol MoleculeLink enables in-body nanobots to transmit information by releasing specific molecules, offering high biocompatibility for medical device communication without radio frequency signals.

Teaching Nanobots to Speak in Molecules

Nanobots working inside the human body face a fundamental challenge: electromagnetic waves attenuate rapidly in bodily fluids, making traditional wireless communication nearly impossible to establish within the body. The molecular communication team at Germany's Max Planck Institute spent six years developing MoleculeLink, a communication protocol that enables nano-scale devices to transmit information by releasing and detecting specific chemical molecules.

MoleculeLink's operating principle draws inspiration from the biological nervous system. The transmitter releases calcium ion pulses at specific concentrations, while the receiver decodes information by detecting concentration changes through biosensors. Single-transmission bandwidth is only 12 bits per second — far below traditional wireless communication — but sufficient for control commands of nano-medical devices.

The research team completed the first end-to-end test in a pig. A 200-micrometer drug delivery robot in the intestine received navigation commands from an external relay station, successfully located a designated inflammation zone, and released medication. Throughout the process, MoleculeLink's signal transmission delay in the bodily fluid environment was 0.3 seconds, with a bit error rate below one in ten thousand.

The Max Planck Institute has signed cooperation agreements with Bayer and Medtronic, planning to launch human clinical trials by the end of 2029. Commercialization of molecular communication will initially target two scenarios: targeted drug delivery and in-body health monitoring.